ClinicalTrials.gg
Status unknownNCT03700593Updated Feb 19, 2020

Feasibility and Safety of Single Port Robot in Colorectal Procedures

An observational study in Colon Cancer, Colon Polyp and Rectal Cancer, sponsored by Marks Colorectal Surgical Associates. Status unknown at 1 site in United States. Open to participants aged 18 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-19.

Sponsored by Marks Colorectal Surgical Associates · Observational

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Enrolling by invitation — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 95 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and feasibility of using the Single Port (SP) robot (daVinci, Intuitive Surgical) to perform single port robotic colon surgery and transanal robotic surgery. The hypothesis of the study is that the SP robot will prove a safe effective modality to perform these procedures.

Read the detailed description

In the colorectal arena, the robotic approach for benign and malignant disease is well established, with a great deal of literature generated regarding the safety and benefits of a colorectal robotic approach for benign and malignant disease. The section of colorectal surgery at the Lankenau Medical Center has been an active and robust contributor to surgical literature on laparoscopic surgery, robotic colorectal surgery, and single port laparoscopic surgery. Its one investigator has been involved in the development of clinical applications to the single port robotic platform where this has been utilized in cadaver work that has been published. Recently, the SP robot has gone through FDA clearance and is now available for clinical utilization. The FDA approval is for urologic surgery. The SP robot will be utilized in the same fashion to perform the same colorectal operations that the investigators have been performing with multiple port placements in the past to accomplish robotic surgery in a single port platform in the colorectal arena. The principal investigator has worked on the SP robot over the past 3 years with extensive cadaver experience to develop its safe application in the colorectal field. This study will entail a collection of demographics, preoperative, perioperative and postoperative outcomes of the patients into a database to follow this, report on the outcomes, and notably answer questions to demonstrate the feasibility and safety of this approach in colorectal patients.

02

Conditions studied

  • Colon Cancer
  • Colon Polyp
  • Rectal Cancer
  • Diverticulitis
  • Prolapse, Rectal
  • Rectal Polyp
  • Inflammatory Bowel Diseases

Keywords

  • Single port robotic surgery
  • Minimally invasive colectomy
  • Single port robotic colectomy
  • Single port robotic TEM
03

In context

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.

This study's planned enrollment of 200 is below the median of 227 across 555 observational studies indexed under Colonic Neoplasms.

Browse Colonic Neoplasms studies →

Lead sponsor

This is the only study on the registry with Marks Colorectal Surgical Associates as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients with a colorectal pathology requiring a minimally invasive colorectal procedure.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients being considered for minimally invasive colorectal surgery will be evaluated for participation in the study.

Exclusion criteria

Exclusion Criteria:

  • emergency surgery
  • inability to offer
  • pregnant patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • Single Port Robotic Colorectal Surgery Patients

    All patients who undergo a single port robot colorectal surgery.

    Device: Single Port Robotic Colorectal Surgery

Interventions

  • DeviceSingle Port Robotic Colorectal Surgery

    Single Port Robotic Colorectal Surgery

06

What researchers measure

Primary outcomes

  1. Feasibility of the SP robot

    Calculating the percentage of cases successfully performed using the SP robot, without conversion.

    Time frame: 30 days

  2. Rate of postoperative complications and mortality of the SP robot

    Measuring the post-operative morbidity and mortality will be used to evaluate the safety of the SP robot.

    Time frame: 30 days

Secondary outcomes

  1. Assessment of patients quality of life using validated questionnaires.

    Validated questionnaire will be administered to assess the quality of life of patients: - RAND 36 item Health Survey (by the RAND corporation): All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. This validated questionnaire asks patients to rate their own health and rate their ability to perform a variety of everyday activities using the same scale.

    Time frame: 1 year

  2. Assessment of patients' satisfaction with their surgical scars using validated questionnaires.

    Validated questionnaire will be administered to assess the patients satisfaction with surgery Patient Scar Assessment Questionnaire (PSAQ)- The PSAQ consists of 5 subscales: Appearance (# of items-9; min-9; max-36), Consciousness (#-6; min-6; max-24), Satisfaction with Appearance (#-8; min-8; max-32) and Satisfaction with Symptoms (#-5; min-5; max-20). Higher scores define more favorable scar appearance, less consciousness of one's scar, increased satisfaction with appearance and symptoms. The scales for each of these subsections is the same; however, min and max scores differ due to differing numbers of questions in each section.

    Time frame: 1 year

  3. Assessment of patient's quality of recovery

    - Quality of Recovery 40 questionnaire: score range: 40-200. Higher values represent better outcomes. The validate questionnaire measure quality of recovery by evaluating patients' comfort, emotions, physical independence, and support using the same scale.

    Time frame: 1 year

  4. Assessment of patients' postoperative body image satisfaction

    Body image questionnaire- 13 items total; min score-13 and max score-100. Higher scores correlate to more favorable body image. In reflecting on their own body image, patients are then asked to rate how likely they would be to undergo a laparoscopic, open, versus single port surgery given their experience. These variables are measured on the same scale.

    Time frame: 1 year

07

Study locations

1 site
  • Lankenau Medical Center, Marks Colorectal Surgical Associates
    Wynnewood, Pennsylvania 19096, United States
08

References and documents

Publications

  • Marks JH, Agarwal S, Kunkel E, Schoonyoung H, Salem JF. Video Demonstration of an Initial Single-Port Robotic Transanal Total Mesorectal Excision. Dis Colon Rectum. 2021 Aug 1;64(8):e472-e473. doi: 10.1097/DCR.0000000000002139. No abstract available. PubMed 34001710 ↗
  • Marks JH, Kunkel E, Salem JF, Martin CT, Anderson B, Agarwal S. First Clinical Experience With Single-Port Robotic Transanal Minimally Invasive Surgery: Phase II Trial of the Initial 26 Cases. Dis Colon Rectum. 2021 Aug 1;64(8):1003-1013. doi: 10.1097/DCR.0000000000001999. PubMed 34001709 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03700593
Lead sponsor
Marks Colorectal Surgical Associates
Responsible party
Dr. John Marks (Chief of Colorectal Surgery, Marks Colorectal Surgical Associates) — Principal investigator
First posted
Oct 9, 2018
Start date
Oct 15, 2018
Primary completion
Oct 1, 2020 (estimated)
Completion
Dec 31, 2020 (estimated)
Last update
Feb 19, 2020

Study contacts

John H Marks, MD
principal investigator · Main Line Health System / Lankenau Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion